Momelotinib 200mg tablets
NHS hospitals in England used £29,363,427 of indicative cost of Momelotinib 200mg tablets in the 12 months to April 2026, about 0.1% of all hospital medicines spend. That is up 40.6% on the previous 12 months.
Indicative cost · 12 months
Quantity (VMP units) · 12 months
Share of hospital medicines spend
Figure 1. Momelotinib 200mg tablets: NHS hospital indicative cost by month (£ millions)
Source: NHSBSA Secondary Care Medicines Data, to April 2026
Cost is indicative — actual hospital medicine prices are commercially confidential, so these figures are estimated from list prices. See methodology.
NHS trusts using Momelotinib 200mg tablets most
By indicative cost over the 12 months to April 2026.
| NHS trust | Indicative cost (12 months) |
|---|---|
| South Tyneside And Sunderland Nhs Ft | £1,107,400 |
| Guy's & St Thomas' Nhs Foundation Trust | £1,064,837 |
| University College London Foundation Tr | £960,500 |
| The Christie Nhs Foundation Trust | £889,687 |
| Derby Teaching Hospitals Nhs Found Trust | £820,757 |
| Western Sussex Hospitals Nhs Found Trust | £760,302 |
| Univ Hpls Bristol Nhs Foundation Trust | £706,250 |
| University Hpls North Midlands Nhs Trust | £686,475 |
| Nottingham University Hospitals Trust | £661,050 |
| United Lincolnshire Hospitals Nhs Trust | £622,630 |
The primary-care picture
No confident match to a community-dispensed medicine was found for this product, so no primary-care comparison is shown. SCMD products are recorded at product level, which does not always map cleanly to a BNF substance.